Health and Healthcare

Are AbbVie Earnings Enough?

AbbVie Inc. (NYSE: ABBV) reported its second-quarter financial results Friday before the markets opened. The pharmaceutical giant had $1.08 in earnings per share (EPS) on $5.48 billion in revenue. That compared to Thomson Reuters consensus estimates of $1.06 in EPS on $5.62 billion in revenue. In the same quarter of the previous year, it posted EPS of $0.82 and $4.93 billion in revenue.

The company confirmed its guidance for 2015; it expects EPS to be $4.10 to $4.30. The consensus analyst estimates are $4.24 in EPS and revenue of $23.35 billion.

Second-quarter sales were driven by the continued strength of Humira and other promoted products.

Gross margin in the second quarter was 85.3%. Its expansion in this quarter was driven by product mix, operating efficiencies and the impact of foreign exchange rates. At the same time, operating margin in the second quarter was 44.2%, compared to 36.4% in second quarter of 2014.

On June 18, the AbbVie board of directors declared a quarterly cash dividend of $0.51 per share, payable August 14, to stockholders of record at the close of business on July 15.

Richard A. Gonzalez, chairman and CEO of AbbVie, said:

We are pleased with the high level of performance we’ve delivered through the first-half of 2015, consistent with our commitment to shareholders for top-tier growth this year and beyond. With the completion of the Pharmacyclics transaction, continued momentum from our on-market products and rapid evolution of our robust development pipeline, we are well positioned to deliver strong performance in the future.

Shares of AbbVie closed Thursday relatively flat at $70.52. Following the release of the earnings report, shares were down 2.9% at $70.52 in early market indications Friday. The stock has a consensus analyst price target of $75.47 and a 52-week trading range of $51.37 to $71.60.

ALSO READ: The Worst Companies to Work For

Are You Still Paying With a Debit Card?

The average American spends $17,274 on debit cards a year, and it’s a HUGE mistake. First, debit cards don’t have the same fraud protections as credit cards. Once your money is gone, it’s gone. But more importantly you can actually get something back from this spending every time you swipe.

Issuers are handing out wild bonuses right now. With some you can earn up to 5% back on every purchase. That’s like getting a 5% discount on everything you buy!

Our top pick is kind of hard to imagine. Not only does it pay up to 5% back, it also includes a $200 cash back reward in the first six months, a 0% intro APR, and…. $0 annual fee. It’s quite literally free money for any one that uses a card regularly. Click here to learn more!

 

Flywheel Publishing has partnered with CardRatings to provide coverage of credit card products. Flywheel Publishing and CardRatings may receive a commission from card issuers.

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.

AI Portfolio

Discover Our Top AI Stocks

Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.

You can follow him investing $500,000 of his own money on our top AI stocks for free.